ArticleScience advances2022
miR-204-containing exosomes ameliorate GVHD-associated dry eye disease.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06002841 (Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies), which is not on this map. Cited by 108 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Extracellular Vesicles From Mesenchymal Cells in the Treatment of Acute Respiratory Failure Associated With SARS-CoV-2 and Other Etiologies: a Clinical Trial, Randomized, Double-blind.
Who cites it
108 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Ocular Surface Disorders.Translational vision science & technology · 2026Pooled it
- Harnessing exosomes in dry eye disease: a triple threat approach.BMC ophthalmology · 2026Pooled it
- A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy.Journal of extracellular vesicles · 2024Pooled it
- Efficacy of topical mesenchymal stem cell exosome in Sjögren's syndrome-related dry eye: a randomized clinical trial.BMC ophthalmology · 2025Trial
- Article
- Small Nucleic Acid Therapeutics for Ocular Diseases: Progress, Challenges, and Future Perspectives.Pharmaceutics · 2026Review
- Activities of human amniotic membrane extracellular vesicles with a focus on ophthalmology.Molecular biology reports · 2026Review
- Delivery of Anti-VEGFA Antibody by Plant-Derived Exosome-like Nanovesicles Alleviates Corneal Angiogenesis and Fibrosis via Topical Ocular Administration.Molecules (Basel, Switzerland) · 2026Article
- Exosomes in the treatment of age-related ophthalmic diseases: an updated review.International ophthalmology · 2026Review
- [Advances in stem cell and exosome-based therapies for dry eye disease].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Review
- Gellan Gum Fluid Gel System for Controlled-Delivery of Cytokine-Licensed MSC-EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency.Advanced healthcare materials · 2026Article
- Stem Cell Therapy: Past, Present, and Future Aspects.Biomedicines · 2026Review
- mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.MedComm · 2026Review
- Research Advances on Mesenchymal Stem Cell-Derived Exosomes in Anti-Graft-Versus-Host Disease Therapy: Mechanisms, Therapeutic Potential, and Future Prospects.International journal of molecular sciences · 2026Review
- Mechanistic Insights Into UC-MSC Therapy in a BAC-Induced Dry Eye Model: TSG-6-Dependent Inhibition of the Th17/CCL20-CCR6 Chemotactic Axis.Investigative ophthalmology & visual science · 2026Article
- The Therapeutic Potential of Exosomes in Ocular Surface Diseases.Biomolecules · 2026Review
- Self-polymerized polyphenol-based platform for the management of dry eye pathogenesis.Nature communications · 2026Article
- The role of natural and engineered exosomes in repairing damage to the nervous system.Journal of nanobiotechnology · 2026Review
- CL-EVLPs Promote Corneal Repair in a BAC-Induced Corneal Injury Model via Ocular Microenvironment Reconstruction.Investigative ophthalmology & visual science · 2026Article
- Extracellular Vesicles in Ophthalmology: From Natural Nanocarriers to Engineered Therapeutics.Bioengineering (Basel, Switzerland) · 2026Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Graft-versus-host disease (GVHD)–associated dry eye disease is characterized by extensive inflammatory destruction in the ocular surface and causes unbearable pain and visual impairment. Current treatments provide limited benefits. Here, we report that exosomes from mesenchymal stromal cells (MSC-exo) administered as eye drops notably alleviate GVHD-associated dry eye disease by suppressing inflammation and improving epithelial recovery in mice and humans. In a prospective clinical trial, 28 eyes with refractory GVHD–dry eye disease exhibited substantial relief after MSC-exo treatment, showing reduced fluorescein scores, longer tear-film breakup time, increased tear secretion, and lower OSDI scores. Mechanistically, MSC-exo reprogramed proinflammatory M1 macrophages toward the immunosuppressive M2 via miR-204–mediated targeting of the IL-6/IL-6R/Stat3 pathway. Blockade of miR-204 abolished the effects of MSC-exo, while overloading L929-exo with miR-204 markedly attenuated dry eye. Thus, this study suggests that MSC-exo are efficacious in treating GVHD-associated dry eye disease and highlights miR-204 as a potential therapeutic agent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.